Novogen Ltd - Report of Foreign Issuer
October 30 2007 - 6:54AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
______________________________________________
Form
6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE
SECURITIES
EXCHANGE ACT OF 1934
For
the
month of October, 2007
Commission
File Number
________________
Novogen
Limited
(Translation
of registrant’s name into English)
140
Wicks
Road, North Ryde, NSW, Australia
(Address
of principal executive office)
___________________________________
Indicate
by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.
Form
20-F
x
Form
40-F
o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(l):
Note:
Regulation S-T Rule 101 (b)( I) only permits the submission in paper of a Form
6-K if submitted solely to provide an attached annual report to security
holders.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule lO1(b)(7):
Note:
Regulation S-T Rule l01(b)(7) only permits the submission in paper of a Form
6-K
if submitted to furnish a report or other document that the registrant foreign
private issuer must furnish and make public under the laws of the jurisdiction
in which the registrant is incorporated, domiciled or legally organized (the
registrant’s “home country”), or under the rules of the home country exchange on
which the registrant’s securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been
distributed to the registrant’s security holders, and, if discussing a material
event, has already been the subject of a Form 6-K submission or other Commission
filing on EDGAR.
Indicate
by check mark whether the registrant by furnishing the information contained
in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule l2g3-2(b) under the Securities Exchange Act of 1934. Yes
o
No
x
If
“Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf
by the undersigned,
thereunto duly authorized.
Novogen
Limited
(Registrant)
/s/ Ron
Erratt
Ronald
Lea Erratt
Company
Secretary
Date
26 October, 2007
ASX
& MEDIA RELEASE
25
OCTOBER, 2007
NOVOGEN
ANNOUNCES COLLABORATION AGREEMENT TO BRING COSMETIC PRODUCTS TO
MARKET
NEW
CANAAN, CT and SYDNEY, Australia, 25 October, 2007 -- Novogen Limited (ASX:
NRT Nasdaq: NVGN) announced today a collaboration agreement to
develop new cosmetic applications. The finished products will be
manufactured and distributed by a leading cosmetics company,
worldwide.
The
partnership matches Novogen’s expertise in the identification, preparation,
analysis and production of compounds with the expertise of a leading global
beauty company.
Preliminary
research shows that a number of Novogen’s compounds have potential in various
cosmetic applications. Novogen’s patent position is an added benefit
to the cosmetics industry at large.
Novogen
retains full rights to wound care applications, treatment of burned tissue,
hair
growth treatments, prescription treatment of skin diseases or skin cancer,
injectables of antidote formulations, or trans-dermal delivery of
pharmaceutical formulations.
Christopher
Naughton, CEO of Novogen, said, “We are proud to be part of the vision,
research, and dedication of the cosmetics industry to skin care and look forward
to a fruitful partnership.”
About
Novogen Limited
Novogen
Limited (Nasdaq: NVGN) is an Australian biotechnology company which has patented
isoflavone technology for the treatment and prevention of degenerative diseases
and disorders. Over the past ten years, Novogen has conducted the largest and
most comprehensive isoflavone clinical testing programs in the world. Novogen
is
involved in drug discovery and product development for disorders that are
commonly associated with aging and coordinates an international clinical
research and development program with external collaborators, hospitals and
universities. For more information,
visit
www.novogen.com
.
Statements
included in this press release that are not historical in nature are
"forward-looking statements" within the meaning of the "safe harbor" provisions
of the Private Securities Litigation Reform Act of 1995. You should be aware
that our actual results could differ materially from those contained in the
forward-looking statements, which are based on management's current expectations
and are subject to a number of risks and uncertainties, including, but not
limited to, our failure to successfully commercialize our product candidates;
costs and delays in the development and/or FDA approval, or the failure to
obtain such approval, of our product candidates; uncertainties in clinical
trial
results; our inability to maintain or enter into, and the risks resulting from
our dependence upon, collaboration or contractual arrangements necessary for
the
development, manufacture, commercialization, marketing, sales and distribution
of any products; competitive factors; our inability to protect our patents
or
proprietary rights and obtain necessary rights to third party patents and
intellectual property to operate our business; our inability to operate our
business without infringing the patents and proprietary rights of others;
general economic conditions; the failure of any products to gain market
acceptance; our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry practice;
and
one-time events. We do not intend to update any of these factors or to publicly
announce the results of any revisions to these forward-looking
statements.
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jul 2023 to Jul 2024